‘Otezula,’ psoriasis therapy, acquires approval from MFDS

Published: 2017-12-12 15:29:06

Updated: 2017-12-12 15:29:06

Celgene Korea(CEO Tae-Jin Ham) announced ‘Otezla(generic name: apremilast),’ an oral selective phosphodiesterase-4(PDE-4) inhibitor, acquired approval from the Ministry of Food and Drug Safety on the 20 November and the company is planning to launch it with the national health insurance benefits.

Otezla, a treatment for adult patients with severe active psoriatic arthritis(PsA), getting genera...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.